U.S. Rare Diseases Treatment Market Size & Outlook
U.S. rare diseases treatment market, 2018-2030 (US$M)
Related Markets
U.S. rare diseases treatment market highlights
- The U.S. rare diseases treatment market generated a revenue of USD 66,676.1 million in 2021 and is expected to reach USD 171,170.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 11% from 2022 to 2030.
- In terms of segment, cancer was the largest revenue generating therapeutic area in 2021.
- Musculoskeletal Conditions is the most lucrative therapeutic area segment registering the fastest growth during the forecast period.
Rare diseases treatment market data book summary
| Market revenue in 2021 | USD 66,676.1 million |
| Market revenue in 2030 | USD 171,170.8 million |
| Growth rate | 11% (CAGR from 2021 to 2030) |
| Largest segment | Cancer |
| Fastest growing segment | Musculoskeletal Conditions |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer, Neurological Conditions, Cardiovascular Conditions, Musculoskeletal Conditions, Hematologic Disorders, Infectious Diseases, Metabolic Diseases, Endocrine Disorders |
| Key market players worldwide | Roche Holding AG, Pfizer Inc, PTC Therapeutics Inc, AstraZeneca PLC, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Bayer AG, AbbVie Inc, Merck & Co Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, U.S. accounted for 59.1% of the global rare diseases treatment market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. rare diseases treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 18,331.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Diseases Treatment Market Scope
Rare Diseases Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. rare diseases treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare diseases treatment market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 28.85% in 2021. Horizon Databook has segmented the U.S. rare diseases treatment market based on cancer, neurological conditions, cardiovascular conditions, musculoskeletal conditions, hematologic disorders, infectious diseases, metabolic diseases, endocrine disorders covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. rare diseases treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. rare diseases treatment market databook
-
Our clientele includes a mix of rare diseases treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. rare diseases treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. rare diseases treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. rare diseases treatment market report size, by therapeutic area, 2018-2030 (US$M)
U.S. Rare Diseases Treatment Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
